Tags

Type your tag names separated by a space and hit enter

Labetalol by continuous intravenous infusion in severe hypertension.
J Clin Hypertens. 1986 Mar; 2(1):39-43.JC

Abstract

This study documents our experience with labetalol administered by continuous intravenous infusion for severe hypertension. Infusions were performed in 14 hospitalized patients (15 infusions) with supine diastolic pressure greater than 125 mmHg or supine systolic pressure greater than 200 mmHg. Blood pressures were measured by intra-arterial recording or an Arteriosonde 1225 Doppler instrument standardized with a mercury sphygmomanometer. Patients initially received 2 mg/min continuous infusion; the infusion rate varied between 0.5 and 2.0 mg/min according to the protocol. The infusion was terminated when diastolic pressure decreased 30 mmHg or when 300 mg of the drug had been infused. Goal blood pressure was achieved in all but two infusions. Sedation was the most common adverse reaction, followed by nausea and diaphoresis. No patient required discontinuation or reduction in infusion rate secondary to side effects. We conclude that continuous intravenous infusion of labetalol offers an effective alternative to current parenteral therapy.

Authors

Wright JT
No affiliation info available
Wilson DJ
No affiliation info available
Goodman RP
No affiliation info available
Minisi AJ
No affiliation info available

MeSH

AdultAgedBlood PressureFemaleHumansHypertensionInfusions, ParenteralLabetalolMaleMiddle Aged

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

3723159

Citation

Wright, J T., et al. "Labetalol By Continuous Intravenous Infusion in Severe Hypertension." Journal of Clinical Hypertension, vol. 2, no. 1, 1986, pp. 39-43.
Wright JT, Wilson DJ, Goodman RP, et al. Labetalol by continuous intravenous infusion in severe hypertension. J Clin Hypertens. 1986;2(1):39-43.
Wright, J. T., Wilson, D. J., Goodman, R. P., & Minisi, A. J. (1986). Labetalol by continuous intravenous infusion in severe hypertension. Journal of Clinical Hypertension, 2(1), 39-43.
Wright JT, et al. Labetalol By Continuous Intravenous Infusion in Severe Hypertension. J Clin Hypertens. 1986;2(1):39-43. PubMed PMID: 3723159.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Labetalol by continuous intravenous infusion in severe hypertension. AU - Wright,J T,Jr AU - Wilson,D J, AU - Goodman,R P, AU - Minisi,A J, PY - 1986/3/1/pubmed PY - 2001/3/28/medline PY - 1986/3/1/entrez SP - 39 EP - 43 JF - Journal of clinical hypertension JO - J Clin Hypertens VL - 2 IS - 1 N2 - This study documents our experience with labetalol administered by continuous intravenous infusion for severe hypertension. Infusions were performed in 14 hospitalized patients (15 infusions) with supine diastolic pressure greater than 125 mmHg or supine systolic pressure greater than 200 mmHg. Blood pressures were measured by intra-arterial recording or an Arteriosonde 1225 Doppler instrument standardized with a mercury sphygmomanometer. Patients initially received 2 mg/min continuous infusion; the infusion rate varied between 0.5 and 2.0 mg/min according to the protocol. The infusion was terminated when diastolic pressure decreased 30 mmHg or when 300 mg of the drug had been infused. Goal blood pressure was achieved in all but two infusions. Sedation was the most common adverse reaction, followed by nausea and diaphoresis. No patient required discontinuation or reduction in infusion rate secondary to side effects. We conclude that continuous intravenous infusion of labetalol offers an effective alternative to current parenteral therapy. SN - 0748-450X UR - https://www.unboundmedicine.com/medline/citation/3723159/Labetalol_by_continuous_intravenous_infusion_in_severe_hypertension_ DB - PRIME DP - Unbound Medicine ER -